Brazilian Health Regulatory Agency authorized Sorrento phase 2 clinical trial of COVI-MSC in COVID-19l long-hauler patients
On Jan. 18, 2022, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a phase 2A randomized, placebo-controlled study of intravenous allogeneic adipose-derived mesenchymal stromal cells to treat post COVID-19 ﾓlong haulﾔ pulmonary compromise.
Tags:
Source: Sorrento Therapeutics
Credit:
